David Adams
Dr. David Adams. Senior Group Leader & Head of Experimental Cancer Genetics, Wellcome Trust Sanger Institute, Hinxton, Cambridge. UK.
Dr. Adams is a senior group leader in the Cancer Ageing and Somatic Mutation programme at the Wellcome Sanger Institute and leads the Experimental Cancer Genetics Laboratory. He is co-head of the Cambridge Cancer Centre Cell and Molecular Biology Programme, a Fellow of the Academy of Medical Sciences and the Royal College of Pathologists, a member of the Scientific Advisory Board (SAB) of the Brain Tumour Charity, and a member of the SAB of the International Laboratory of Human Genome Research. He is also a founding member of the atlas of variant effects consortium and a member of the steering committee of the Society for Melanoma Research, and co-chairs Genomel (The Genetics of Melanoma Consortium). His group uses large-scale genomic studies and genome editing to identify cancer genes and explore their function.
Dave is co-head of the Sanger Excellence Programme for Black British scientist (with Dr. Saher Ahmed) and is involved in advocacy efforts for cancer genetic studies in LMICs, particularly with Latin American countries, work which is funded by the MRC and Royal Society.
Outside of work Dave is a keen distance runner (10Km and half Marathons), a consumer of copious quantities of coffee and a failed vegetarian.
Abstracts this author is presenting: